On July 31, Natera rose 5.08% in regular trading, trading at $266.715/share, with turnover of $143 million. The rally was driven by a confluence of positive catalysts ahead of the company's upcoming quarterly earnings release on August 6.

On the earnings front, market consensus expects Q2 revenue of approximately $661 million, representing 38.72% year-over-year growth, with adjusted EPS loss narrowing to -$0.49, an improvement of 19.84% from the prior year period. The company previously guided full-year revenue of $2.74B-$2.82B, above analyst estimates.

Multiple Signatera catalysts provided additional momentum. In July, Signatera received EU IVDR Class C certification covering multiple solid tumor types including gastrointestinal, lung, breast, skin, and gynecological cancers, supporting continued EU commercialization beyond 2028. Additionally, a study published in JAMA Dermatology demonstrated Signatera detected Merkel cell carcinoma recurrence with 90% sensitivity versus 55% for the standard AMERK test, with a median lead time of 5.1 months compared to 2.1 months.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)